SUSTAINABLE DESIGN EVALUATION – INTEGRATION OF SUSTAINABILITY IN PRODUCT DEVELOPMENT PROCESSES

To develop sustainable products, product developers must be able to incorporate sustainability into individual decision processes during product development. In doing so, they are faced with the conflicting demands of time and cost pressure and the growing complexity caused by the many requirements and (sustainability) criteria. The Sustainable Design Evaluation, which is presented in this publication, is a method to enable product developers to estimate the impact of their product-related decisions along the three dimensions of sustainability across all phases of the product life cycle. The core of the Sustainable Design Evaluation is a two-stage assessment technique enabling a relative and comparable quantification of ecological, economic, and social criteria. Furthermore, an aggregation scheme for those criteria is introduced. Based on the two-stage assessment technique and the system of aggregation, the results of the Sustainable Design Evaluation can be displayed clearly and interpreted easily by product developers to assess the impacts of their product-related decisions. Thus, in contrast to existing methods, the SDE combines ease of use and interpretation with a sufficiently holistic sustainability assessment

Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication

Pharmacological targeting of metabolic processes in cancer must overcome redundancy in biosynthetic pathways. Deoxycytidine (dC) triphosphate (dCTP) can be produced both by the de novo pathway (DNP) and by the nucleoside salvage pathway (NSP). However, the role of the NSP in dCTP production and DNA synthesis in cancer cells is currently not well understood. We show that acute lymphoblastic leukemia (ALL) cells avoid lethal replication stress after thymidine (dT)-induced inhibition of DNP dCTP synthesis by switching to NSP-mediated dCTP production. The metabolic switch in dCTP production triggered by DNP inhibition is accompanied by NSP up-regulation and can be prevented using DI-39, a new high-affinity small-molecule inhibitor of the NSP rate-limiting enzyme dC kinase (dCK). Positron emission tomography (PET) imaging was useful for following both the duration and degree of dCK inhibition by DI-39 treatment in vivo, thus providing a companion pharmacodynamic biomarker. Pharmacological co-targeting of the DNP with dT and the NSP with DI-39 was efficacious against ALL models in mice, without detectable host toxicity. These findings advance our understanding of nucleotide metabolism in leukemic cells, and identify dCTP biosynthesis as a potential new therapeutic target for metabolic interventions in ALL and possibly other hematological malignancies

Development of New Deoxycytidine Kinase Inhibitors and Noninvasive in Vivo Evaluation Using Positron Emission Tomography

Combined inhibition of ribonucleotide reductase and deoxycytidine kinase (dCK) in multiple cancer cell lines depletes deoxycytidine triphosphate pools leading to DNA replication stress, cell cycle arrest and apoptosis. Evidence implicating dCK in cancer cell proliferation and survival stimulated our interest in developing small molecule dCK inhibitors. Following a high throughput screen of a diverse chemical library, a structure-activity relationship study was carried out. Positron Emission Tomography (PET) using (18)F-L-1-(2′-deoxy-2′-FluoroArabinofuranosyl) Cytosine ((18)F-L-FAC), a dCK-specific substrate, was used to rapidly rank lead compounds based on their ability to inhibit dCK activity in vivo. Evaluation of a subset of the most potent compounds in cell culture (IC(50) = ∼1 – 12 nM) using the (18)F-L-FAC PET pharmacodynamic assay identified compounds demonstrating superior in vivo efficacy